+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Transdermal nicotine use in postmenopausal women: does the treatment efficacy differ in women using and not using hormone replacement therapy?



Transdermal nicotine use in postmenopausal women: does the treatment efficacy differ in women using and not using hormone replacement therapy?



Nicotine and Tobacco Research 6(5): 777-788



This study of postmenopausal female smokers (N = 94) asked: During short-term smoking abstinence, do the beneficial effects of transdermal nicotine replacement therapy (NRT) on acute symptomatology (i.e., withdrawal, cigarette craving, smoking urges, mood, depressive symptoms, motor speed, and reaction time) differ in women who use and do not use hormone replacement therapy (HRT)? Participants were recruited according to HRT and non-HRT use (self-selecting), then randomized within strata to active nicotine or placebo nicotine patch. After 1 baseline week of smoking, participants quit smoking for 2 weeks. Women received cessation counseling and were monitored for abstinence. Dependent measures were collected during five clinic visits. Two-way analysis of covariance (ANCOVA) were run on change scores for dependent variables, with nicotine patch group (active/placebo) and HRT group (HRT/non-HRT) as independent variables and age as a covariate. No interactions were found between HRT and patch condition, but both showed specific effects. During the first abstinent week, women on active nicotine patch (compared with placebo) experienced less severe withdrawal, greater reductions in cigarette cravings, and lower (more favorable) Factor 1 scores on the Questionnaire of Smoking Urges. During the second abstinent week, women using HRT (compared with the non-HRT group) exhibited better mood (Profile of Mood States scores) and less depression (Beck Depression Inventory scores). These results suggest the following: First, the efficacy of transdermal nicotine replacement is not adversely modified by women's HRT use; second, ovarian hormones might influence women's responses to smoking cessation, and thus should be considered in developing effective strategies for women to quit smoking.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 050817445

Download citation: RISBibTeXText

PMID: 15700913


Related references

Transdermal nicotine use in postmenopausal women: Does the treatment efficacy differ in women using and not using hormone replacement therapy?. Nicotine & Tobacco Research 6(5): 777-788, 2004

Efficacy and tolerability of fully transdermal hormone replacement in sequential or continuous therapy at two doses of progestogen in postmenopausal women. Maturitas 37(2): 83-93, December 29, 2000

Efficacy and tolerability of fully transdermal hormone replacement in sequential or continuous therapy at two doses of progestogen in postmenopausal women. Maturitas 37(2): 83-93, 2001

Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolaemia among postmenopausal women. Journal of Internal Medicine 238(1): 39-47, 1995

Efficacy of treatment with combined hormone replacement therapy for hyperlipidemia among postmenopausal women. Circulation 90(4 PART 2): I363, 1994

Transdermal Hormone Replacement Therapy in Postmenopausal Women With Uterine Leiomyomas. Obstetrics & Gynecology 98(6): 1053-1058, 2001

Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas. Obstetrics & Gynecology 98(6): 1053-1058, 2001

Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas. Obstetrics and Gynecology 98(6): 1053-1058, 2002

Hormone replacement therapy does not prevent coronary heart disease and is associated with increased overall risk for health of postmenopausal women. Final results of studies on hormone replacement therapy efficacy in frame of Women's Health Initiative and data from other recent studies. Kardiologiia 43(9): 77-79, 2004

Serum leptin levels in postmenopausal women: effects of transdermal hormone replacement therapy. Menopause 7(1): 36-41, 2000

Urinary cGMP excretion after oral and transdermal hormone replacement therapy in postmenopausal women. European Journal of Clinical Pharmacology 52(SUPPL ): A82, 1997

Breast cancer after hormone replacement therapy--does prognosis differ in perimenopausal and postmenopausal women?. Breast 20(5): 448-454, 2012

Insulin resistance and short-term transdermal hormone replacement therapy in hypertensive postmenopausal women. Journal of Hypertension 18(Suppl 4): S133, 2000

Serum leptin levels and body weight in postmenopausal women under transdermal hormone replacement therapy. European Journal of Medical Research 5(2): 63-66, 2000

Effects of transdermal hormone replacement therapy on levels of soluble P- and E-selectin in postmenopausal healthy women. Fertility & Sterility 77(3): 476-480, 2002